期刊
ADVANCED SCIENCE
卷 6, 期 4, 页码 -出版社
WILEY
DOI: 10.1002/advs.201801585
关键词
diagnosis; epidemiology; nonalcoholic fatty liver disease (NAFLD); pathogenesis; treatments
资金
- National Science Fund for Distinguished Young Scholars [81425005]
- Key Project of the National Natural Science Foundation [81330005, 81630011]
- National Science and Technology Support Project [2014BAI02B01, 2015BAI08B01]
- National Key Research and Development Program [2013YQ030923-05, 2016YFF0101504]
- Key Collaborative Project of the National Natural Science Foundation [91639304]
- National Science Foundation of China [81570271, 81770053]
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease which affects approximate to 25% of the adult population worldwide, placing a tremendous burden on human health. The disease spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and ultimately, cirrhosis and carcinoma, which are becoming leading reasons for liver transplantation. NAFLD is a complex multifactorial disease involving myriad genetic, metabolic, and environmental factors; it is closely associated with insulin resistance, metabolic syndrome, obesity, diabetes, and many other diseases. Over the past few decades, countless studies focusing on the investigation of noninvasive diagnosis, pathogenesis, and therapeutics have revealed different aspects of the mechanism and progression of NAFLD. However, effective pharmaceuticals are still in development. Here, the current epidemiology, diagnosis, animal models, pathogenesis, and treatment strategies for NAFLD are comprehensively reviewed, emphasizing the outstanding breakthroughs in the above fields and promising medications in and beyond phase II.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据